In randomized TORCH-PM01, adding FAPI-guided hypofractionated RT and cadonilimab to second-line systemic therapy increased objective response from 15% to 60% and conversion to cytoreductive surgery from 20% to 60%.
Standardized joint contours showed that higher D50% and mean joint dose were associated with grade ≥2 stiffness after extremity sarcoma RT.
Faster PSA rise after testosterone recovery tracked progression, but associations with distant metastasis were inconsistent and too imprecise for clinical inference.
Across 744 cervical oART fractions, RTT-led adaptation took a median 33 minutes while maintaining ≥95% target D98 in every fraction.
After repeat spine SBRT, 12-month local failure was 6% with Dmin ≥28 Gy EQD2 versus 36% below that level.
Across 286 HDR monotherapy patients, higher EQD2 D90 was not associated with biochemical control or overall survival.
Four-day multicatheter HDR partial-breast irradiation produced 3.8% ipsilateral recurrence at 15 years with exclusively grade 1-2 recorded late toxicity.
Severe fatigue, sleep disturbance and drowsiness during oropharyngeal cancer RT were independently associated with substantially worse overall survival.
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
Grade ≥2 GI toxicity was 14% with oART versus 45% with IGRT, with better preservation of several HRQoL domains.
A 28-fraction SIB course shortened postoperative soft tissue sarcoma radiotherapy by about one week, with no significant matched outcome or toxicity differences.
Across 32 years of T1 anal cancer treatment, five-year colostomy-free survival reached 85.3%, with no treatment-related colostomies.
Central thoracic re-irradiation achieved 80.1% one-year local control, while cumulative esophageal V60 emerged as a potential toxicity signal.
Video and printed education performed similarly, while half of patients preferred video and self-reported anxiety fell from 30% to 5%.
Accelerator-based BNCT produced an 80% response and 51.1% two-year survival, but two-year local control was 31.8% with substantial toxicity.